A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes

NCT00458159 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
34
Enrollment
INDUSTRY
Sponsor class

Stopped The compound has a benign safety profile with short-term use, clinically sig efficacy responses have not been demonstrated, or if so, have not been sustained.

Conditions

Interventions

Sponsor

Celgene